Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461010 | 0.79 | SLC5A2 (0.47) | SLC5A2ESR1 | |
| SCHEMBL460784 | 0.75 | PREP (0.39) | SLC5A2 | |
| SCHEMBL15443986 | 0.72 | ESR1 (0.42) | ESR1 | |
| SCHEMBL469637 | 0.72 | SLC5A2 (0.35) | SLC5A2 | |
| SCHEMBL10135674 | 0.71 | SLC5A2 (0.48) | SLC5A2 | |
| SCHEMBL13078449 | 0.70 | ESR1 (0.43) | ESR1 | |
| SCHEMBL12309927 | 0.69 | ESR1 (0.61) | ESR1 | |
| SCHEMBL13541142 | 0.67 | ALDH1A1 (0.35) | ESR1 | |
| SCHEMBL15457714 | 0.67 | ESR1 (0.43) | ESR1 | |
| SCHEMBL15443987 | 0.67 | ESR1 (0.43) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885ESR1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.